The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein.
Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet.
The English language version is always the official and authoritative version of this website.
NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window.
Synopsis As Introduced Amends the Illinois Public Aid Code. Provides that the Department shall not impose requirements for prior approval based on a preferred drug list for any short-acting beta agonists used as rescue therapy in the treatment of life-threatening conditions due to acute bronchospasm in patients with reversible obstructive airway disease that results from asthma, chronic obstructive pulmonary disease or emphysema.
Fiscal Note (Department of Public Aid)
This bill will hamper the Department's ability to enact cost containment measures if prior approval, generic preference and formulary restrictions are exempt for clients diagnosed with a specific disease such as reversible obstructive airway disease. If the Department is unable to require prior approval on any products of this type, the additional cost is estimated to be $2-5 million.
Fiscal Note (Department of Public Aid)
This bill will hamper the Department's ability to enact cost containment measures if prior approval, generic preference and formulary restrictions are exempt for clients diagnosed with a specific disease such as reversible obstructive airway disease. If the Department is unable to require prior approval on any products of this type, the additional cost is estimated to be $2-5 million.
This site is maintained for the Illinois General Assembly
by the Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706
Contact ILGA Webmaster